AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Kalkine:ASX 200-Medical Device Makers Lead Healthcare Sector
June 05, 2025 01:52 PM AEST| By Team Kalkine MediaHighlights,ASX-listed medical device manufacturers show resilience in contrast to declining biotech valuations in the US,Nasdaq Biotechnology Index has declined, while US medtech ETFs recorded gains over the past year,ASX companies such as ResMed (AS...
Kalkine : ASX 200 Mining and Healthcare Leaders-Mineral Resources and ResMed Overview
June 05, 2025 01:02 PM AEST| By Team Kalkine MediaHighlights,Mineral Resources Limited (ASX:MIN) operates in lithium and iron ore mining, supported by integrated engineering services across multiple Australian states.,ResMed CDI (ASX:RMD) focuses on cloud-connected medical equipment for sleep apnea...
Kalkine: Mayne Pharma Sees Share Boost Amid Cosette Takeover Uncertainty
June 04, 2025 02:54 PM AEST| By Team Kalkine MediaHighlights,Mayne Pharma's share price climbs as Cosette Pharmaceuticals has not formally withdrawn its takeover proposal,FDA issues letter indicating prior concerns around Nextstellis have been resolved,Mayne Pharma reiterates its position on materia...
Kalkine: Mayne Pharma (ASX:MYX) Lifts as Cosette Keeps Takeover Door Open
June 04, 2025 02:39 PM AEST| By Team Kalkine MediaHighlights,Mayne Pharma shares advanced as Cosette Pharmaceuticals has not yet withdrawn its takeover offer,The company addressed FDA concerns that were previously flagged as material by Cosette,Takeover developments come amid broader activity on the...
Kalkine: ASX200 Shock: Cosette Walks Away from $672M Mayne Pharma Deal Amid Earnings & Regulatory Woes
June 04, 2025 02:21 PM AEST| By Team Kalkine MediaHighlights,Cosette seeks to end $672 million Mayne Pharma deal,Mayne Pharma rejects claims of financial deterioration,Regulatory and earnings concerns spark investor reaction,In a significant shake-up for the,ASX200,, U.S.-based pharmaceutical firm C...
Kalkine: Why Sonic Healthcare (ASX:SHL) Could Be a Key Contender in the ASX200 Healthcare Space
June 04, 2025 01:51 PM AEST| By Team Kalkine MediaHighlights,SHL shares trading below 5-year average valuation,Healthcare sector offers stable long-term potential,Ethical and defensive traits boost sector appeal,Sonic Healthcare Ltd (ASX:SHL) has long stood as a significant player in the global heal...
Kalkine: Chimeric Therapeutics’ Breakthrough Cancer Therapy Gains FDA Fast-Track: A Promising Leap for ASX200 Biotech Space
June 04, 2025 11:58 AM AEST| By Team Kalkine MediaHighlights,Chimeric Therapeutics receives FDA fast-track status for cancer drug,Novel CAR-T therapy targets unmet need in gastrointestinal,tumours,Ongoing clinical trial builds momentum for potential treatment,Chimeric Therapeutics (ASX:CHM) has take...
Kalkine: Mayne Pharma's $672 Million Deal with Cosette Faces Uncertainty Amid ASX200 Volatility
June 04, 2025 11:14 AM AEST| By Team Kalkine MediaHighlights,Mayne Pharma warns Cosette may still,terminate,acquisition offer,FDA concerns and financial performance cited as key issues,ASX dividend stocks,remain,in focus amid pharma sector m,The proposed $672 million acquisition of Mayne Pharma Grou...
Kalkine: Mayne Pharma Faces ASX200 Uncertainty as Cosette Remains Silent on $672M Takeover
June 04, 2025 10:52 AM AEST| By Team Kalkine MediaHighlights,Mayne Pharma awaits clarity from Cosette on proposed deal,FDA concerns addressed, says Mayne,Share price trades well below offer value,Mayne Pharma (ASX:MYX) finds itself in a critical phase as it awaits a formal response from US-based Cos...
Kalkine: Is Nanosonics (ASX:NAN) Staying Resilient Despite Weak Price Trends?
June 03, 2025 02:33 PM AEST| By Team Kalkine MediaHighlights,Nanosonics operates within the healthcare sector and is listed on the ASX 200,The company’s return on equity aligns with broader industry benchmarks,Profits are being retained and reinvested, supporting earnings growth,Nanosonics Limited (...
Kalkine: ASX 200 Biotech Stocks Show Signs of Resilience Despite Choppy May
June 03, 2025 02:25 PM AEST| By Team Kalkine MediaHighlights,MedAdvisor and Dimerix record strong market cap increases,Emvision and Paradigm advance pivotal clinical trials,Select companies complete capital raisings amid funding challenges,The Australian biotechnology sector, part of the broader,ASX...
Kalkine: ASX 200 Biotech Stock Recce Pharmaceuticals Advances After Capital Raise Completion
June 03, 2025 01:57 PM AEST| By Team Kalkine MediaHighlights,Recce Pharmaceuticals Ltd (ASX:RCE) completes shortfall placement to finalise broader capital raising initiative,Proceeds to fund key clinical programs focused on antibiotic-resistant infection treatments,Trials include diabetic foot infec...
Race Oncology Plans Investor Engagement Drive in June with ASX300 Spotlight
June 02, 2025 04:30 PM AEST| By Team Kalkine MediaHighlights,Race Oncology (RAC) to present at June investor events,Key updates on lead asset bisantrene (RC220) to be shared,Brisbane investor briefing scheduled for June 27,Race Oncology (ASX:RAC), a clinical-stage biotechnology company focused on pr...
Kalkine| ASX 200 Biotech Stock Imugene Expands Bowel Cancer Vaccine Trial to Australia
June 02, 2025 02:59 PM AEST| By Team Kalkine MediaHighlights,Imugene Ltd (ASX:IMU, OTC:IUGNF) initiates Australian enrolment for its Phase II Neo-POLEM study,The trial assesses PD1-Vaxx immunotherapy for a genetically distinct form of colorectal cancer,Conducted in partnership with leading cancer re...
Orthocell CEO Reaches EY Entrepreneur Finals as ASX 200 Health Sector Advances
June 02, 2025 02:47 PM AEST| By Team Kalkine MediaHighlights,Paul Anderson, CEO of Orthocell Ltd (ASX:OCC, OTC:ORHHF), selected as finalist in EY Entrepreneur Of The Year Australia awards,Orthocell strengthens commercial footprint with Remplir™ nerve repair device and global distribution deals,ASX 2...
Kalkine: Imugene Expands Global Cancer Vaccine Trial, Adding Momentum to ASX200 Biotech Landscape
June 02, 2025 11:43 AM AEST| By Team Kalkine MediaHighlights,Imugene,activates Australian site for Phase II bowel cancer vaccine trial,PD1-Vaxx targets hard-to-treat genetic subtype of colorectal cancer,Study focuses on pre-surgical immune response and long-term outcomes,Imugene Ltd (ASX:IMU) has ma...
Kalkine: Opthea Board Shake-Up Amid Trial Setback and Workforce Cuts: Impact on ASX200 Landscape
June 02, 2025 10:35 AM AEST| By Team Kalkine MediaHighlights,Four,Opthea,directors exit after clinical trial setback,Company slashes workforce by 65% amid,restructuring,Trading,remains,suspended on ASX and Nasdaq,Biotech company,Opthea (ASX:OPT),is undergoing major changes after a significant clinic...
Kalkine: Opthea Board Shake-Up: Director Exodus After Clinical Trial Failure Hits ASX200 Biotech (ASX:OPT)
June 02, 2025 10:29 AM AEST| By Team Kalkine MediaHighlights,Four directors resign from,Opthea,amid clinical trial failure,OPT-302 trial setbacks raise solvency concerns,Ongoing talks continue with primary funders,In a major development impacting the Australian biotech landscape, Opthea Ltd (ASX:OPT...
Kalkine: Beamtree’s Strategic UK Move Boosts Global Footprint with NHS Partnership
May 30, 2025 03:51 PM AEST| By Team Kalkine MediaHighlights,Beamtree partners with NHS Confederation for UK hospital analytics,Launch of Evolve Collaborative planned by late 2025,$1.5M investment to drive expansion and innovation,Healthcare data specialist Beamtree Holdings (ASX:BMT) is taking a bo...
Kalkine| ASX 200 Healthcare Stock Ramsay Soars After Strategic Board Appointment
May 30, 2025 03:28 PM AEST| By Team Kalkine MediaHighlights,Ramsay Health Care (ASX:RHC) appoints Craig Drummond as Non-Executive Director, effective from July,Market responds with strong share movement amid positive sentiment in the healthcare sector,Broader transformation and governance focus ref...
Advertise your brand on Kalkine Media